J Viallet
Overview
Explore the profile of J Viallet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
935
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kroiss A, Vincent S, Decaussin-Petrucci M, Meugnier E, Viallet J, Ruffion A, et al.
Oncogene
. 2014 Jul;
34(22):2846-55.
PMID: 25065599
Androgen signaling, via the androgen receptor (AR), is crucial in mediating prostate cancer (PCa) initiation and progression. Identifying new downstream effectors of the androgens/AR pathway will allow a better understanding...
2.
Dong S, Kang S, Lonial S, Khoury H, Viallet J, Chen J
Leukemia
. 2007 Dec;
22(3):572-7.
PMID: 18079735
Small molecule tyrosine kinase inhibitors, such as imatinib, are effective therapies for BCR-ABL-mediated human leukemias. However, clinical drug resistance occurs, which warrants development of alternative and/or complementary therapeutic strategies to...
3.
Ravel A, Perez N, Privat C, Blanc C, Thieblot P, Viallet J, et al.
J Radiol
. 2000 Aug;
81(7):781-6.
PMID: 10915991
Purpose: Evaluate the MR sensibility for detection and localisation of ACTH-secreting microadenomas of the pituitary gland. Patients: and method. The MRI studies of the pituitary gland, performed before transsphenoidal surgical...
4.
von Pawel J, Von Roemeling R, Gatzemeier U, Boyer M, Elisson L, Clark P, et al.
J Clin Oncol
. 2000 Mar;
18(6):1351-9.
PMID: 10715308
Purpose: A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus...
5.
Bedikian A, Legha S, Eton O, Buzaid A, Papadopoulos N, Plager C, et al.
Anticancer Drugs
. 1999 Nov;
10(8):735-9.
PMID: 10573206
A phase II study was undertaken to determine the efficacy of tirapazamine combined with cisplatin in patients with metastatic melanoma between April 1996 and April 1997. Tirapazamine 390 mg/m2, administered...
6.
Viallet J, Brassard M, Souhami L, Ayoub J, Del Vecchio P, Kreisman H, et al.
Cancer
. 1999 Jun;
85(12):2562-9.
PMID: 10375103
Background: Both locoregional and distant disease control remains poor in the treatment of Stage III nonsmall cell lung carcinoma (NSCLC). This trial was conducted to evaluate the tolerance and responses...
7.
Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, et al.
J Clin Oncol
. 1998 Nov;
16(11):3524-7.
PMID: 9817270
Purpose: A phase II study was conducted to evaluate the safety and efficacy of tirapazamine combined with cisplatin for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Patients...
8.
Tsao M, Liu N, Nicklee T, Shepherd F, Viallet J
Clin Cancer Res
. 1998 Nov;
3(10):1807-14.
PMID: 9815567
A total of 195 non-small cell lung carcinoma (NSCLC) specimens were studied for the presence of mutations in their ras family genes, for tumor vascularity, and for their immunostaining pattern...
9.
Tsao M, Liu N, Chen J, Pappas J, Ho J, To C, et al.
Lung Cancer
. 1998 Aug;
20(1):1-16.
PMID: 9699182
Hepatocyte growth factor (HGF)/scatter factor (SF) is a multifunctional factor that stimulates epithelial cell motility, invasion and morphogenesis. Its receptor is a transmembrane tyrosine kinase encoded by the Met proto-oncogene....
10.
Yi S, Chen J, Viallet J, Schwall R, Nakamura T, Tsao M
Br J Cancer
. 1998 Jul;
77(12):2162-70.
PMID: 9649128
We have studied the mitogenic, motogenic and morphogenic effects of hepatocyte growth factor (HGF), also known as scatter factor (SF), on 15 non-small-cell lung carcinoma (NSCLC) cell lines that have...